(Q36247723)

13 August 2017

1 reference

title

Preclinical testing of new vaccines for tuberculosis: a comprehensive review (English)

1 reference

13 August 2017

0 references

1

Ian M Orme

1 reference

13 August 2017

language of work or name

English

0 references

publication date

8 August 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

2-19

1 reference

A proposed national strategy for tuberculosis vaccine development

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

New vaccines against tuberculosis. The status of current research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis vaccine development: recent progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Prospects for better tuberculosis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Is the development of a new tuberculosis vaccine possible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Current progress in tuberculosis vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Non-human primates: a model for tuberculosis research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Animal models for experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The mouse as a useful model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The Intravenous Model of Murine Tuberculosis is Less Pathogenic Than the Aerogenic Model Owing to a More Rapid Induction of Systemic Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

ExperimentalMycobacterium tuberculosisInfection of Cynomolgus Macaques Closely Resembles the Various Manifestations of HumanM. tuberculosisInfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Disseminated tuberculosis in interferon gamma gene-disrupted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

IL-4 in tuberculosis: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Cytokine/chemokine cascades in immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunology of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunology: remembrance of things past

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Phagosomes are competent organelles for antigen cross-presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Old mice express a transient early resistance to pulmonary tuberculosis that is mediated by CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Improving vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis vaccines: developmental work and the future.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunological requirements for a subunit vaccine against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Antigen discovery and tuberculosis vaccine development in the post-genomic era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Crossprotection against nontuberculous mycobacterial infections by Mycobacterium tuberculosis memory immune T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunization of mice with mycobacterial culture filtrate proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

T cell response to Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Boosting vaccine for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

inferred from DOI database lookup

7 January 2021

based on heuristic

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Prospects for a better vaccine against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis vaccine development; from mouse to man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

On the use of DNA vaccines for the prophylaxis of mycobacterial diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

DNA vaccination: the answer to stable, protective T-cell memory?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Improved tuberculosis DNA vaccines by formulation in cationic lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The immunogenicity of single and combination DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Therapy of tuberculosis in mice by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Evaluation of the protective potency of new tuberculosis vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mycobacterium leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Developing an improved vaccine against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

BCG--different strains, different vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Comparative genomics of BCG vaccines by whole-genome DNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Development of live recombinant vaccine candidates against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

From evil to good: a cytolysin in vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mycobacterium tuberculosis H37Rv: Delta RD1 is more virulent than M. bovis bacille Calmette-Guérin in long-term murine infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Tuberculosis subunit vaccine development: on the role of interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

What do microarrays really tell us about M. tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

The tuberculosis vaccine challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Characterization of the secreted antigens of Mycobacterium bovis BCG: comparison of the 46-kilodalton dimeric protein with proteins MPB64 and MPB70.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

inferred from DOI database lookup

7 January 2021

based on heuristic

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.078

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.07.078

1 reference

13 August 2017

1 reference